The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
CORONARY INTERVENTIONS
DESyne novolimus-eluting coronary stent is superior to Endeavor zotarolimus-eluting coronary stent at five-year follow-up: final results of the multicentre EXCELLA II randomised controlled trial
EuroIntervention 2016;12:e1336-e1342 published online ahead of print October 2015 published online e-edition December 2016. DOI: 10.4244/EIJY15M10_04
Javaid Iqbal1, MRCP, PhD; Stefan Verheye2, MD, PhD; Alexandre Abizaid3, MD, PhD; John Ormiston4, MB ChB; Ton de Vries5, MSc; Lynn Morrison6, MPH; Sara Toyloy6, BS; Peter Fitzgerald7, MD, PhD; Stephan Windecker8, MD, PhD; Patrick W. Serruys1,9*, MD, PhD; on behalf of EXCELLA II Investigators
1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Academisch Ziekenhuis Middelheim, Antwerp, Belgium; 3. Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil; 4. Auckland City Hospital, Auckland, New Zealand; 5. Cardialysis BV, Rotterdam,
Aims: Newer-generation drug-eluting stents (DES) have been shown to be superior to first-generation DES. Current-generation DES have zotarolimus, everolimus or biolimus as antiproliferati